Submit to JPM Review for JPM Propose a Special Issue

Journal Browser

Personalized Diagnosis and Treatment of Pulmonary Diseases

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 15678

Share This Special Issue

Special Issue Editor

Prof. Dr. Hyun Lee

E-Mail Website
Guest Editor

Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Korea
Interests: asthma; bronchiectasis; COPD; cough; Mycobacterial pulmonary diseases; lung cancer; other lung diseases

Special Issue Information

Dear Colleagues,

“Personalized medicine” has achieved great progress in the diagnosis and treatment of pulmonary diseases. However, due to the heterogeneous presentation, treatment response, and prognosis of many pulmonary diseases, we are still facing unmet requirements to give a better outcome beyond “today’s personalized medicine”. We need more studies connecting phenotypes to endotypes, which can help to identify potential biomarkers and treatable traits in various pulmonary diseases. This Special Issue of the Journal of Personalized Medicine aims to provide the latest studies in the personalized diagnosis and treatment of pulmonary diseases, especially in the field of airway diseases (asthma, bronchiectasis, and chronic obstructive pulmonary disease (COPD)), cough, mycobacterial pulmonary diseases, lung cancer, and other lung diseases. We welcome clinical or translational studies evaluating phenotypes or endotypes of pulmonary diseases using advanced techniques (e.g., omics technologies (genomics and epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, imaging, and functional analyses), health big data analyses, observational studies, etc.).

Prof. Dr. Hyun Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

Asthma
Bronchiectasis
COPD
Cough
Lung cancer
Mycobacterial disease
Personalized medicine
Biomarker
Treatable trait
Endotype

Published Papers (5 papers)

Download All Papers

Research

Jump to: Review

14 pages, 4064 KiB

Open AccessArticle

Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension

by Marcin Waligóra, Barbara Żuławinska, Michał Tomaszewski, Pere Roset and Grzegorz Kopeć

J. Pers. Med. 2023, 13(3), 423; https://doi.org/10.3390/jpm13030423 - 26 Feb 2023

Cited by 1 | Viewed by 2398

Abstract

Background and Objectives: Parenteral prostacyclins are crucial in the pharmacological treatment of pulmonary arterial hypertension (PAH). Indeed, subcutaneous administration of treprostinil has been associated with considerable clinical and hemodynamic improvement, right-sided heart reverse remodeling, and long-term survival benefit. However, evidence on patient perceptions about handling a subcutaneous infusion pump for self-treatment administration and nurse views about training the patients are lacking. This study aimed to describe the perception of PAH patients and nurses regarding the use of the new portable I-Jet infusion pump for the self-administration of subcutaneous treprostinil, as well as its real-world training needs. Materials and Methods: The study is an open, observational, prospective, single-center, non-interventional study. Patients with PAH on stable therapy with subcutaneous treprostinil were invited to take part in the study at their start of use of the portable I-Jet infusion pump for the self-administration of treatment. Participants filled in a questionnaire to report their satisfaction with the use of the pump, as well as their compliance, confidence, convenience, preferences, technical issues, and perceptions of the training they received. Results: Thirteen patients completed the questionnaire after being on the pump for 2 months: 69% were females and the mean age was 51 years. The most frequent PAH etiologies were congenital heart disease (46.2%) and idiopathic PAH (38.4%). Most patients were either World Health Organization (WHO) functional class II (53.8%) or III (46.2%). Ten patients (76.9%) found the pump easy and convenient to live with. All patients declared themselves to be fully compliant and confident in using the pump (n = 13) at the end of the study follow-up. Ten patients (76.9%) would choose the new pump in the future. None of the patients made reference to technical issues that required additional hospital visits. Eight patients (61.6%) reported that learning how to use the I-Jet infusion pump was easy or very easy, and none considered that further training was needed. One trainer nurse was interviewed and confirmed the satisfaction of patients and the simplicity of usage and training. Conclusions: PAH patients were highly satisfied with the use of the new portable I-Jet infusion pump for self-administering subcutaneous treprostinil. Convenience and ease of use were valuable and commonly reported features. Moreover, the training requirement was simple. These preliminary findings support the routine use of the I-Jet infusion pump. Full article

(This article belongs to the Special Issue Personalized Diagnosis and Treatment of Pulmonary Diseases)

► Show Figures

Graphical abstract

10 pages, 560 KiB

Open AccessArticle

Impact of Previous Occupational Exposure on Outcomes of Chronic Obstructive Pulmonary Disease

by Youlim Kim, Tai Sun Park, Tae-Hyung Kim, Chin Kook Rhee, Changhwan Kim, Jae Seung Lee, Woo Jin Kim, Seong Yong Lim, Yong Bum Park, Kwang Ha Yoo, Sang-Do Lee, Yeon-Mok Oh and Ji-Yong Moon

J. Pers. Med. 2022, 12(10), 1592; https://doi.org/10.3390/jpm12101592 - 27 Sep 2022

Viewed by 1360

Abstract

Occupational exposures have been regarded as a risk factor for the development of chronic obstructive pulmonary disease (COPD). However, there is little knowledge regarding the effect of occupational exposure on the treatment outcomes of COPD. Therefore, the aim of this study was to evaluate the question of whether occupational exposure can have a potential impact on COPD outcomes. Methods: Information regarding self-reported occupational exposure for 312 patients with COPD from the Korean Obstructive Lung Disease (KOLD) Cohort were included. A comparison of the rate of acute exacerbation, annual lung function change, and quality of life according to the presence or absence of occupational exposure was performed. Results: Seventy-six patients (24.4%) had experienced occupational exposure; chemical materials were most common. At enrollment, a higher COPD-specific version of the St. George Respiratory Questionnaire total score (39.7 ± 18.8 vs. 33.1 ± 17.6, p = 0.005) and a higher exacerbation history in the past year (30.3% vs. 17.5%, p = 0.017) were observed for patients with occupational exposure compared to those without occupational exposure. Furthermore, in the follow-up period, after adjusting for potential confounders, a higher frequency of acute exacerbation (odd ratio, 1.418; 95% confidence interval, 1.027–1.956; p = 0.033) and a more rapid decline in forced expiratory volume in 1 s (p = 0.009) was observed for COPD patients with occupational exposure compared to those without occupational exposure. Conclusions: In the KOLD cohort, worse outcomes in terms of exacerbation rate and change in lung function were observed for COPD patients with occupational exposure compared to those without occupational exposure. These findings suggest that occupational exposure not only is a risk factor for COPD but also might have a prognostic impact on COPD. Full article

(This article belongs to the Special Issue Personalized Diagnosis and Treatment of Pulmonary Diseases)

► Show Figures

Figure 1

13 pages, 1004 KiB

Open AccessArticle

Lack of Association between Inhaled Corticosteroid Use and the Risk of Future Exacerbation in Patients with GOLD Group A Chronic Obstructive Pulmonary Disease

by Sun Hye Shin, Deog Kyeom Kim, Sang-Heon Kim, Tae Rim Shin, Ki-Suck Jung, Kwang Ha Yoo, Ki-Eun Hwang, Hye Yun Park, Yong Suk Jo and on behalf of the KOCOSS Cohort

J. Pers. Med. 2022, 12(6), 916; https://doi.org/10.3390/jpm12060916 - 31 May 2022

Viewed by 2118

Abstract

Background: As most clinical trials have been performed in more symptomatic and higher-risk patients, evidence regarding treatment in patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A chronic obstructive pulmonary disease (COPD) is limited. We assessed the distribution of inhaler treatment and sought to investigate the association between inhaled corticosteroid (ICS) use and future exacerbation in GOLD group A COPD patients. Methods: Patients with GOLD group A COPD who received maintenance inhalers were identified from a multicentre, prospective cohort in South Korea. Patients were categorized as group A when they had fewer symptoms and did not experience severe exacerbation in the previous year. Development of moderate or severe exacerbation during the 1-year follow-up was analysed according to baseline inhaler treatment. Results: In 286 patients with GOLD group A COPD, mono-bronchodilator (37.8%), dual-bronchodilator (29.0%), triple therapy (17.5%), and ICS/long-acting beta-2 agonist (15.4%) were used. Compared to patients without ICS-containing inhalers (N = 191), those using ICS (N = 95) were more dyspnoeic, and more likely to have asthma history, lower lung function, and bronchodilator response. During the 1-year follow-up, moderate or severe exacerbations occurred in 66 of 286 (23.1%) patients. In the multivariable logistic regression analysis, ICS-containing inhaler use was not associated with the development of exacerbation, even in the subgroup with a high probability of asthma–COPD overlap. Conclusion: Although about one-third of patients with GOLD group A COPD were using ICS-containing inhalers, use of ICS was not associated with a reduction in the future development of exacerbation. Full article

(This article belongs to the Special Issue Personalized Diagnosis and Treatment of Pulmonary Diseases)

► Show Figures

Figure 1

12 pages, 1242 KiB

Open AccessArticle

Correlation Comparison and Personalized Utility of Field Walking Tests in Assessing the Exercise Capacity of Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial

by Eun Jae Ko, Jang Ho Lee, Hyang Yi Lee, Seong Ho Lee, Hack-Jae Lee, Ganghee Chae, Sei Won Lee and Seung Won Ra

J. Pers. Med. 2022, 12(6), 901; https://doi.org/10.3390/jpm12060901 - 30 May 2022

Cited by 1 | Viewed by 2001

Abstract

Background: Incremental shuttle walking tests (ISWT) are regarded as valuable alternatives to 6-min walking tests (6MWT) and cardiopulmonary exercise tests (CPET) owing to the maximal and externally paced loading. This study investigated the validity and reliability of ISWT by analyzing the correlation of the distances of two field tests with peak oxygen consumption (VO₂) of CPET in patients with COPD. Methods: In this randomized controlled trial, patients with COPD were enrolled from two hospitals. Three assessments were performed for all patients. The ISWT and 6MWT were repeated twice in Hospital 1 to assess reliability. Results: A total of 29 patients were enrolled. The distances of ISWT (0.782, p < 0.001) and 6MWT (0.512, p = 0.005) correlated with peak VO₂. The intraclass correlation coefficients of both ISWT (0.988, p < 0.001) and 6MWT (0.959, p < 0.001) was high. Patients with higher peak VO₂ walked a longer distance in ISWT than 6MWT (r = 0.590, p < 0.001). Conclusions: The ISWT more highly correlates with peak VO₂ than the 6MWT and has excellent reliability in patients with COPD. According to peak VO₂, the walking distances of each field test varied, suggesting that the application should be personalized for the exercise capacity. Full article

(This article belongs to the Special Issue Personalized Diagnosis and Treatment of Pulmonary Diseases)

► Show Figures

Figure 1

Review

Jump to: Research

19 pages, 2807 KiB

Open AccessEditor’s ChoiceReview

Endotypes of Prematurity and Phenotypes of Bronchopulmonary Dysplasia: Toward Personalized Neonatology

by Maria Pierro, Karen Van Mechelen, Elke van Westering-Kroon, Eduardo Villamor-Martínez and Eduardo Villamor

J. Pers. Med. 2022, 12(5), 687; https://doi.org/10.3390/jpm12050687 - 26 Apr 2022

Cited by 26 | Viewed by 7146

Abstract

Bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, is increasingly recognized as the consequence of a pathological reparative response of the developing lung to both antenatal and postnatal injury. According to this view, the pathogenesis of BPD is multifactorial and heterogeneous with different patterns of antenatal stress (endotypes) that combine with varying postnatal insults and might distinctively damage the development of airways, lung parenchyma, interstitium, lymphatic system, and pulmonary vasculature. This results in different clinical phenotypes of BPD. There is no clear consensus on which are the endotypes of prematurity but the combination of clinical information with placental and bacteriological data enables the identification of two main pathways leading to birth before 32 weeks of gestation: (1) infection/inflammation and (2) dysfunctional placentation. Regarding BPD phenotypes, the following have been proposed: parenchymal, peripheral airway, central airway, interstitial, congestive, vascular, and mixed phenotype. In line with the approach of personalized medicine, endotyping prematurity and phenotyping BPD will facilitate the design of more targeted therapeutic and prognostic approaches. Full article

(This article belongs to the Special Issue Personalized Diagnosis and Treatment of Pulmonary Diseases)

► Show Figures